NRG Oncology/RTOG 0415, hypofractionation in patients with low-risk prostate cancer: are patient reported outcomes the practice change tipping point?

被引：0
|
作者：
Pugh, Stephanie L. [1 ]
Lee, W. R. [2 ]
Dignam, James [1 ]
Low, Daniel [3 ]
Swanson, Gregory P. [4 ]
Shah, Amit B. [5 ]
D'Souza, David P. [6 ]
Michalski, Jeff M. [7 ]
Dayes, Ian S. [8 ]
Seaward, Samantha A. [9 ]
Nguyen, Paul L. [10 ]
Hall, William A. [11 ]
Pisansky, Thomas M. [12 ]
Chen, Yuhchyau [13 ]
Sandler, Howard M. [14 ]
Movsas, Benjamin [15 ]
Bruner, Deborah W. [16 ]
机构：
[1] NRG Oncol, Philadelphia, PA USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[5] WellSpan Hlth York Canc Ctr, York, PA USA
[6] London Reg Canc Program, London, ON, Canada
[7] Washington Univ, St Louis, MO USA
[8] McMaster Univ, Juravinski Canc Ctr, Hamilton Hlth Sci, Hamilton, ON, Canada
[9] Kaiser Permanente Northern Calif, Santa Clara, CA USA
[10] Dana Farber Harvard Canc Ctr, Boston, MA USA
[11] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[12] Mayo Clin, Scottsdale, AZ USA
[13] Univ Rochester, Rochester, NY USA
[14] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[15] Henry Ford Hosp, Detroit, MI 48202 USA
[16] Emory Univ, Atlanta, GA 30322 USA
来源：
QUALITY OF LIFE RESEARCH | 2017年 / 26卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
206.2
引用
收藏
页码：38 / 39
页数：2
相关论文
共 50 条
  • [21] Permanent seed brachytherapy for low-risk prostate cancer: Longterm outcomes at the Catalan Institute of Oncology
    Miguelez, C. Gutierrez
    Daidone, A.
    Perez, E. Martinez
    Fabregas, J. Pera
    Gonzalez, F. Ferrer
    Inglada, A. M. Boladeras
    Gonzalez, S. Botella
    Sorroche, Pino
    Novo, Suarez
    Edo, Guedea
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S152 - S153
  • [22] Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non -Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer
    Lee, W. R.
    Dignam, J. J.
    Amin, M.
    Bruner, D. W.
    Low, D.
    Swanson, G. P.
    Shah, A. B.
    D'Souza, D. P.
    Michalski, J. M.
    Dayes, I.
    Seaward, S. A.
    Hall, W. A.
    Nguyen, P. L.
    Pisansky, T. M.
    Faria, S. L.
    Chen, Y.
    Rodgers, J.
    Sandler, H. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S3 - S4
  • [23] Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial
    Movsas, B.
    Rodgers, J.
    Elshaikh, M. A.
    Martinez, A. A.
    Morton, G.
    Krauss, D. J.
    Yan, D.
    Citrin, D. E.
    Hershatter, B.
    Michalski, J. M.
    Ellis, R. J., III
    Kavadi, V. S.
    Gore, E. M.
    Gustafson, G. S.
    Schulz, C. A.
    Velker, V.
    Olson, A. C.
    Karrison, T. G.
    Sandler, H. M.
    Bruner, D. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S3 - S3
  • [24] Psychological predictors of delayed active treatment following active surveillance for low-risk prostate cancer: The Patient REported outcomes for Prostate cARE prospective cohort study
    Taylor, Kathryn L.
    Luta, George
    Zotou, Vasiliki
    Lobo, Tania
    Hoffman, Richard M.
    Davis, Kimberly M.
    Potosky, Arnold L.
    Li, Tengfei
    Aaronson, David
    Van Den Eeden, Stephen K.
    BJUI COMPASS, 2022, 3 (03): : 226 - 237
  • [25] The evolving landscape of practice pattern and survival outcomes in the management of localized low-risk prostate cancer.
    Mao, Shifeng S.
    Schorr, Rebecca
    Wegner, Rodney E.
    Fuhrer, Russell
    Miller, Ralph
    Lyne, John
    Cohen, Jeffrey
    Samiei, Arash
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17057 - E17057
  • [26] PATHOLOGIC OUTCOMES IN PATIENTS AFFECTED BY VERY-LOW-RISK AND LOW-RISK PROSTATE CANCER AND ELIGIBLE FOR ACTIVE SURVEILLANCE
    Napodano, Giorgio
    Realfonso, Tommaso
    Intilla, Olivier
    Pistone, Antonio
    Addesso, Maria
    Sanseverino, Roberto
    ANTICANCER RESEARCH, 2017, 37 (04) : 2081 - 2082
  • [27] Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically
    Louie-Johnsun, Mark
    Neill, Mischel
    Treurnicht, Karien
    Jarmulowicz, Michael
    Eden, Christopher
    BJU INTERNATIONAL, 2009, 104 (10) : 1501 - 1504
  • [28] PATHOLOGICAL OUTCOMES IN PATIENTS WITH CLINICALLY LOW-RISK PROSTATE CANCER DEEMED ELIGIBLE FOR ACTIVE SURVEILLANCE
    Srivastava, A.
    Grover, S.
    Sooriakumaran, P.
    Leung, R.
    Tewari, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 333 - 333
  • [29] Pathologic outcomes in patients with clinically low-risk prostate cancer deemed eligible for active surveillance
    Srivastava, A.
    Grover, S.
    Sooriakumaran, P.
    Rajan, S.
    El-Douaihy, Y.
    Tewari, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [30] Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Miyamoto, H
    Messing, EM
    Chang, CS
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (05): : 236 - 237
12345